LENZ Therapeutics, Inc. Common Stock

LENZNASDAQ • USD
ThemeBiotech - Drug Development›Clinical-Stage Platforms
4.59 USD
↘ 0.09 (1.92%)AT CLOSE (11:59 AM EDT)
4.67
↗ 0.08 (1.83%)
POST MARKET (AS OF 07:41 PM EDT)
Post Market
AS OF 07:41 PM EDT
4.67
↗ 0.08 (1.83%)
🔴Market: CLOSED

Shares of LENZ Therapeutics, Inc. Common Stock (LENZ) are trading at $4.61. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". Notable factors include a weak Piotroski F-Score of 1/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics place LENZ at a fair price relative to peers.

Technical & fundamental data as of Aug 24, 2026.

Open?$4.65
High?$4.70
Low?$4.55
Prev. Close?$4.68
Volume?497.9K
Avg. Volume?898.3K
VWAP?$4.62
Rel. Volume?0.55x
Bid / Ask
Bid?$4.55 × 100
Ask?$4.70 × 18.8K
Spread?$0.15
Midpoint?$4.63
Valuation & Ratios
Market Cap?144.2M
Shares Out?31.4M
Float?14.1M
Float %?44.9%
P/E Ratio?N/A
P/B Ratio?0.66
EPS?-$4.01
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
Themes
Biotech - Drug Development›Clinical-Stage PlatformsLongevity & Aging›Age-Related Therapeutics
Employees
152
Market Cap
147.0M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.lenz-tx.com
Listed
2024-03-22
Address
201 LOMAS SANTA FE DRIVE, SUITE 300
SOLANA BEACH, CA 92075
Phone: 858-925-7000
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
54
Momentum?
48
Short Sent.?
30
Piotroski F-Score?1/9Weak
Altman Z-Score?2.51Grey
Confidence?58%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?80.37%Squeeze Risk
Short Interest?11.3M
Days to Cover?11.8
Free Float14.1M
Avg Daily Volume957.8K
Settlement Date2026-07-31
Financial Health
Current Ratio?13.55Strong
Quick Ratio?13.31Strong
Cash Ratio?1.41Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.66CHEAP▾
P/S?
Peers
100
S&P
18
6.72FAIR▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.9CHEAP▾
EV/Sales?
Peers
100
S&P
31
5.59FAIR▾
Returns & Efficiency
ROE?
S&P
3
-57.5%WEAK▾
ROA?
S&P
3
-53.2%WEAK▾
Cash Flow & Enterprise
FCF?$-114419000
Enterprise Value?$120.0M
Fundamentals ratios updated end of day
MarketsMoversWatchlist